Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
About
Company Overview
Leadership
Scientific Advisory Board
Collaborations
Technology
Stimulant Abuse
How it Works
Mechanism of Action
Clinical Data
Publications
Pipeline
Overview
ADAIR
ADMIR
ADHD
Narcolepsy
Patient Resources
Newsroom
Investors
Investors
Press Releases
Events + Presentations
Company Information
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
News Alerts
Contact
Vallon Pharmaceuticals and
GRI Bio
Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators
We hosted a joint webcast on December 14, 2022 – Access the Webcast Replay
Here
Investors
Press
Releases
Overview
Press Releases
Events + Presentations
Company Information
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
News Alerts
Recent Press Releases
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
February 24, 2023
Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event
January 11, 2023
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators
December 13, 2022
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 3, 2022
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 28, 2022
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
May 13, 2022
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
May 11, 2022
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 9, 2022
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
April 22, 2022
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
March 23, 2022
Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
March 21, 2022
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
February 28, 2022
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
February 28, 2022
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
February 14, 2022
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022
Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
January 18, 2022
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
January 4, 2022
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
December 23, 2021
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 12, 2021
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
November 11, 2021
Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
November 10, 2021
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
November 1, 2021
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
October 12, 2021
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
September 14, 2021
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
August 11, 2021
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
July 13, 2021
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
May 11, 2021
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
May 7, 2021
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 3, 2021
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 23, 2021
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 9, 2021
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 8, 2021
Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 9, 2020
Vallon Newsroom
Close Menu
About
Company Overview
Leadership
Scientific Advisory Board
Collaborations
Technology
Stimulant Abuse
How it Works
Mechanism of Action
Clinical Data
Publications
Pipeline
Overview
ADAIR
ADMIR
ADHD
Narcolepsy
Patient Resources
Newsroom
Investors
Investors
Press Releases
Events + Presentations
Company Information
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
News Alerts
Contact